The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
UBC News
  • Home
  • News Tips
  • Arts & Humanities
  • Business, Law & Society
  • Science, Health & Technology
  • University News
  • Contacts
  • Services
    • Services for Journalists
    • Services for Faculty
Home / lopinavir-ritonavir

lopinavir-ritonavir

Global COVID-19 treatment trial shows current antivirals are of little benefit to hospitalized patients

Interim results from the Solidarity Therapeutics Trial indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.

Oct 16, 2020

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Credit: CDC/Unsplash

Canadian COVID-19 trial gets additional $3.5 million in federal funding

The Canadian arm of a major international clinical trial—led by a University of British Columbia researcher—that aims to find the best treatment for COVID-19 has received an additional $3.5 million in funding from the federal government through the Canadian Institutes of Health Research (CIHR).

May 28, 2020

News Tips

News Tips

Looking for story ideas?
Check out our latest News Tips!

Find UBC Experts

An information source that gives journalists access to UBC’s expertise.

Explore

  • Arts & Humanities
  • Business, Law & Society
  • Science, Health & Technology
  • University News
  • Q&As
  • Media Advisories
  • Latest News

Tweets by @ubcnews

My Tweets
Subscribe & receive news by e-mail View UBC's Okanagan News Room
    
Public Affairs
310 - 6251 Cecil Green Park Road
Vancouver, BC Canada V6T 1Z1
Tel 604 822 6397
Fax 604 822 2684
Website news.ubc.ca
Email public.affairs@ubc.ca
Find us on
    
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility